Replies to post #74570 on OWC Pharmaceutical Research Corp (OWCP)

[Lo$eitall80]

DEA Schedules Insys Therapeutics’ Syndros (dronabinol oral solution) as Schedule II Drug

Positive news for MMJ generally that the DEA has finally made a decision that this cannabinoid-based medicine can be moved from Schedule 1.


http://finance.yahoo.com/news/dea-schedules-i...25023.html OUR BUDDY TRIPLE 9 POSTED THIS ELSEWHERE!! :)